FrancophonIA/ELRC3.0 huggingface dataset:
English: Patients treated with any antipsychotic medicines, including ZYPREXA VELOTAB, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia, and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control.
Croatian: U bolesnika liječenih bilo kojim antipsihotikom, uključujući lijek ZYPREXA VELOTAB, treba pratiti pojavu znakova i simptoma hiperglikemije (kao što su polidipsija, poliurija, polifagija i slabost), a bolesnike s dijabetesom melitusom ili čimbenicima rizika za razvoj dijabetesa melitusa treba redovito pratiti zbog mogućeg pogoršanja glikemije.
English: Children and adolescents ZYPREXA VELOTAB is not for patients who are under 18 years.
Croatian: ZYPREXA VELOTAB nije za primjenu u bolesnika mlađih od 18 godina.
English: Reversible neutropenia, thrombocytopenia, or anaemia developed in a few dogs treated with 8 or 10 mg/kg/day (total olanzapine exposure [area under the curve] is 12- to 15-fold greater than that of a man given a 12-mg dose).
Croatian: Reverzibilna neutropenija, trombocitopenija ili anemija razvile su se u malog broja pasa liječenih dozom od 8 ili 10 mg/kg/dan (ukupna izloženost olanzapinu [AUC] je 12 do 15 puta veća nego izloženost u čovjeka kojemu je dana doza od 12 mg).
English: In placebo-controlled clinical trials (6-12 weeks duration) of elderly patients (mean age 78 years) with dementia-related psychosis and/or disturbed behaviours, there was a 2-fold increase in the incidence of death in olanzapine-treated patients compared to patients treated with placebo (3.5% vs. 1.5 %, respectively).
Croatian: U placebom kontroliranim kliničkim ispitivanjima (trajanja od 6 do 12 tjedana) starijih bolesnika (srednja vrijednost dobi 78 godina) s psihozom i/ili poremećajima ponašanja uzrokovanima demencijom zabilježeno je dvostruko povećanje incidencije smrtnosti u bolesnika liječenih olanzapinom u usporedbi s bolesnicima koji su primali placebo (3,5% naspram 1,5%).
English: The most frequently (seen in ≥ 1% of patients ) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema.
Croatian: Najčešće prijavljene nuspojave (uočene u ≥ 1% bolesnika) povezane s primjenom olanzapina u kliničkim ispitivanjima bile su somnolencija, povećanje tjelesne težine, eozinofilija, povišene vrijednosti prolaktina, kolesterola, glukoze i triglicerida (vidjeti dio 4.4), glikozurija, povećan apetit, omaglica, akatizija, parkinsonizam, leukopenija, neutropenija (vidjeti dio 4.4), diskinezija, ortostatska hipotenzija, antikolinergički učinci, prolazni asimptomatski porasti vrijednosti jetrenih aminotransferaza (vidjeti dio 4.4), osip, astenija, umor, pireksija, artralgija, povišena razina alkalne fosfataze, visoka razina gama glutamiltransferaze, visoka razina mokraćne kiseline, visoka razina kreatin fosfokinaze i edem.
English: If you suddenly stop taking ZYPREXA VELOTAB, symptoms such as sweating, unable to sleep, tremor, anxiety or nausea and vomiting might occur.
Croatian: Ako naglo prestanete s uzimanjem lijeka ZYPREXA VELOTAB mogu se pojaviti simptomi poput znojenja, nesanice, nevoljnog drhtanja, tjeskobe ili mučnine i povraćanja.
English: An allergic reaction may be recognised as a rash, itching or shortness of breath.
Croatian: Alergijsku reakciju možete prepoznati kao osip, svrbež ili nedostatak zraka.
English: < 1.467 mmol/l) to high (≥ 1.467 mmol/l).
Croatian: (≥ 1,016 mmol/l-< 1,467 mmol/l) do visokih vrijednosti (≥ 1,467 mmol/l).
English: ZYPREXA VELOTAB contains sodium methyl parahydroxybenzoate and sodium propyl parahydroxybenzoate, which may cause an allergic reaction in some people.
Croatian: ZYPREXA VELOTAB sadrži natrijev metilparahidroksibenzoat i natrijev propilparahidroksibenzoat, koji mogu uzrokovati alergijsku reakciju u nekih osoba.
English: If this happens after you have been given ZYPREXA VELOTAB tell your doctor.
Croatian: Vam se ovo pojavi nakon uzimanja lijeka ZYPREXA VELOTAB, obratite se svom liječniku.
English: What you need to know before you take ZYPREXA VELOTAB
Croatian: Što morate znati prije nego počnete uzimati ZYPREXA VELOTAB
English: ZYPREXA VELOTAB tablets break easily, so you should handle the tablets carefully.
Croatian: ZYPREXA VELOTAB tablete lako se lome te njima treba pažljivo rukovati.
English: Separate one blister cell from the strip.
Croatian: Odvojite jedno polje blistera od ostatka trake.
English: 28 orodispersible tablets 35 orodispersible tablets 56 orodispersible tablets 70 orodispersible tablets 98 orodispersible tablets
Croatian: 28 raspadljivih tableta za usta 35 raspadljivih tableta za usta 56 raspadljivih tableta za usta 70 raspadljivih tableta za usta 98 raspadljivih tableta za usta
English: Patients who cannot take phenylalanine should note that ZYPREXA VELOTAB contains aspartame, which is a source of phenylalanine.
Croatian: Bolesnici koji ne smiju uzimati fenilalanin moraju znati da ZYPREXA VELOTAB sadrži aspartam, koji je izvor fenilalanina.
English: However, since patients with schizophrenia often present with acquired risk factors for venous thromboembolism all possible risk factors of VTE e.g. immobilisation of patients, should be identified and preventive measures undertaken.
Croatian: Međutim, budući da bolesnici sa shizofrenijom često imaju stečene čimbenike rizika za vensku tromboemboliju, sve moguće čimbenike rizika za VTE npr. imobilizacija bolesnika,
English: The following table summarises the adverse reactions reported with a greater frequency in adolescent patients (aged 13-17 years) than in adult patients or adverse reactions only identified during short term clinical trials in adolescent patients.
Croatian: Sljedeća tablica sažima nuspojave prijavljene s većom učestalošću u adolescentnih bolesnika (u dobi od 13 do 17 godina) u odnosu na odrasle bolesnike ili nuspojave identificirane samo u kratkotrajnim kliničkim ispitivanjima u adolescentnih bolesnika.
English: Olanzapine orodispersible tablets may be used as an alternative to olanzapine coated tablets.
Croatian: Olanzapin raspadljive tablete za usta mogu se koristiti kao alternativa obloženim tabletama olanzapina.
English: Patients treated with any antipsychotic medicines, including ZYPREXA VELOTAB, should be monitored regularly for lipids in accordance with utilised antipsychotic guidelines, e.g. at baseline, 12 weeks after starting olanzapine treatment and every 5 years thereafter.
Croatian: U bolesnika liječenih bilo kojim antipsihotikom, uključujući lijek ZYPREXA VELOTAB, potrebno je redovito pratiti razinu lipida prema smjernicama za primjenu antipsihotika, na primjer, na početku liječenja, 12 tjedana nakon početka liječenja olanzapinom te svakih 5 godina nakon toga.
English: Patients who cannot take mannitol should note that ZYPREXA VELOTAB contains mannitol.
Croatian: Bolesnici koji ne smiju uzimati manitol moraju znati da ZYPREXA VELOTAB sadrži manitol.
English: What ZYPREXA VELOTAB contains
Croatian: Što ZYPREXA VELOTAB sadrži
English: In renally impaired patients (creatinine clearance < 10 ml/min) versus healthy subjects, there was no significant difference in mean elimination half-life (37.7 versus 32.4 hr) or clearance (21.2 versus 25.0 l/hr).
Croatian: U bolesnika s oštećenjem bubrega (klirens kreatinina < 10 ml/min) nije bilo značajne razlike u odnosu na zdrave ispitanike u prosječnom poluvremenu eliminacije (37,7 naspram 32,4 sata) ili klirensu (21,2
English: If this happens do not drive or operate any tools or machines.
Croatian: nemojte upravljati vozilima niti rukovati bilo kakvim alatima ili strojevima.
English: • unusual movement (a common side effect that may affect up to 1 in 10 people) mainly of the face or tongue;
Croatian: Odmah obavijestite svog liječnika ako imate: • neuobičajene pokrete (česta nuspojava koja se može pojaviti u najviše 1 na 10 osoba) uglavnom na licu ili jeziku;
English: Hyperglycaemia and/or development or exacerbation of diabetes occasionally associated with ketoacidosis or coma has been reported uncommonly, including some fatal cases (see section 4.8).
Croatian: Hiperglikemija i dijabetes Manje su često prijavljivane hiperglikemija i/ili razvoj ili egzacerbacija dijabetesa ponekad povezani s ketoacidozom ili komom, uključujući neke smrtne slučajeve (vidjeti dio 4.8).
English: If you stop taking ZYPREXA VELOTAB
Croatian: Ako prestanete uzimati ZYPREXA VELOTAB
English: An updated RMP should be submitted: • At the request of the European Medicines Agency
Croatian: • na zahtjev Europske agencije za lijekove;
English: Talk to your doctor or pharmacist before you take ZYPREXA VELOTAB
Croatian: Upozorenja i mjere opreza Obratite se svom liječniku ili ljekarniku prije nego uzmete ZYPREXA VELOTAB.
English: unusual movements (especially of the face or tongue) and reduced level of consciousness.
Croatian: ubrzan rad srca, uznemirenost/agresivnost, poteškoće s govorom, neuobičajene pokrete (osobito lica ili jezika) i sniženu razinu svijesti.
English: (See sections 4.5 and 5.2.)
Croatian: (vidjeti dio 4.6)
English: What ZYPREXA VELOTAB looks like and contents of the pack ZYPREXA VELOTAB 5 mg, 10 mg, 15 mg and 20 mg are yellow orodispersible tablets.
Croatian: Kako ZYPREXA VELOTAB izgleda i sadržaj pakiranja ZYPREXA VELOTAB 5 mg, 10 mg, 15 mg i 20 mg su žute raspadljive tablete za usta.
English: There was a 3-fold increase in CVAE in patients treated with olanzapine compared to patients treated with placebo (1.3 % vs. 0.4 %, respectively).
Croatian: U bolesnika liječenih olanzapinom zabilježen je trostruki porast CV štetnih događaja u usporedbi s bolesnicima koji su primali placebo (1,3% naspram 0,4%).
English: EU/1/99/125/006 EU/1/99/125/007 EU/1/99/125/008 EU/1/99/125/009 EU/1/99/125/010 EU/1/99/125/011 EU/1/99/125/012 EU/1/99/125/013 EU/1/99/125/014 EU/1/99/125/015 EU/1/99/125/016 EU/1/99/125/017 EU/1/99/125/018 EU/1/99/125/019 EU/1/99/125/020
Croatian: EU/1/99/125/001 EU/1/99/125/002 EU/1/99/125/003 EU/1/99/125/004 EU/1/99/125/005 EU/1/99/125/006 EU/1/99/125/007 EU/1/99/125/008 EU/1/99/125/009 EU/1/99/125/010 EU/1/99/125/011 EU/1/99/125/012 EU/1/99/125/013 EU/1/99/125/014 EU/1/99/125/015 EU/1/99/125/016 EU/1/99/125/017
English: Haematologic toxicity: Effects on haematology parameters were found in each species, including dose-related reductions in circulating leukocytes in mice and non-specific reductions of circulating leukocytes in rats; however, no evidence of bone marrow cytotoxicity was found.
Croatian: U svakoj su vrsti pronađeni učinci na hematološke parametre, uključujući smanjenje broja cirkulirajućih leukocita ovisno o dozi u miševa te nespecifično smanjenje broja cirkulirajućih leukocita u štakora.
English: Rare side effects (may affect up to 1 in 1000 people) include lowering of normal body temperature; abnormal rhythms of the heart; sudden unexplained death; inflammation of the pancreas causing severe stomach pain, fever and sickness; liver disease appearing as yellowing of the skin and white parts of the eyes; muscle disease presenting as unexplained aches and pains; and prolonged and/or painful erection.
Croatian: Rijetke nuspojave (mogu se pojaviti u najviše 1 na 1000 osoba) uključuju sniženje normalne tjelesne temperature; poremećaj srčanog ritma; naglu neobjašnjivu smrt; upalu gušterače koja uzrokuje jaku bol u trbuhu, vrućicu i mučninu; bolest jetre koja se očituje žutilom kože i bjeloočnica; bolest mišića koja se manifestira neobjašnjivim bolovima; te produljenu i/ili bolnu erekciju.
English: It has the same dosage and frequency of administration as olanzapine coated tablets.
Croatian: Ima isto doziranje i učestalost primjene kao obložene tablete olanzapina.
English: In cases where dose increments of 2.5 mg are considered necessary, ZYPREXA coated tablets should be used.
Croatian: Kada je potrebno povećavati dozu u koracima od 2,5 mg, treba primjenjivati ZYPREXA obložene tablete. (Vidjeti dijelove 4.5 i 5.2.)
English: ZYPREXA VELOTAB 5 mg orodispersible tablets ZYPREXA VELOTAB 10 mg orodispersible tablets ZYPREXA VELOTAB 15 mg orodispersible tablets ZYPREXA VELOTAB 20 mg orodispersible tablets
Croatian: ZYPREXA VELOTAB 5 mg raspadljive tablete za usta ZYPREXA VELOTAB 10 mg raspadljive tablete za usta ZYPREXA VELOTAB 15 mg raspadljive tablete za usta ZYPREXA VELOTAB 20 mg raspadljive tablete za usta
English: There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder.
Croatian: hipotoniji, tremoru, somnolenciji, respiratornom distresu ili poremećaju hranjenja.
English: Uncommon side effects (may affect up to 1 in 100 people) include hypersensitivity (e.g. swelling in the mouth and throat, itching, rash); diabetes or the worsening of diabetes, occasionally associated with ketoacidosis (ketones in the blood and urine) or coma; seizures, usually associated with a history of seizures (epilepsy); muscle stiffness or spasms ( including eye movements); restless legs syndrome; problems with speech; stuttering; slow heart rate; sensitivity to sunlight; bleeding from the nose; abdominal distension; memory loss or forgetfulness; urinary incontinence; lack of ability to urinate; hair loss; absence or decrease in menstrual periods; and changes in breasts in males and females such as an abnormal production of breast milk or abnormal growth.
Croatian: Manje česte nuspojave (mogu se pojaviti u najviše 1 na 100 osoba) uključuju preosjetljivost (npr. oticanje u ustima i grlu, svrbež; osip); šećernu bolest ili pogoršanje šećerne bolesti, ponekad povezano s ketoacidozom (ketonima u krvi i mokraći) ili komom; napadaje, obično povezane s napadajima u povijesti bolesti (epilepsija); mišićnu ukočenost ili grč (uključujući pokrete očiju); sindrom nemirnih nogu; poteškoće s govorom; mucanje; usporen rad srca; osjetljivost na sunčevu svjetlost; krvarenje iz nosa; nadimanje trbuha; gubitak pamćenja ili zaboravljivost; nemogućnost zadržavanja mokraće (inkontinencija); nemogućnost mokrenja; ispadanje kose; izostanak ili smanjenje mjesečnice i promjene na grudima u muškaraca i žena, kao što je poremećaj stvaranja majčinog mlijeka ili abnormalan rast.
English: Mannitol ZYPREXA VELOTAB orodispersible tablet contains mannitol.
Croatian: Manitol ZYPREXA VELOTAB raspadljive tablete za usta sadrže manitol.
English: Other symptoms may be: acute confusion, seizures (epilepsy), coma, a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness, slowing of the breathing rate, aspiration, high blood pressure or low blood pressure, abnormal rhythms of the heart.
Croatian: koma, kombinacija vrućice, ubrzanog disanja, znojenja, ukočenosti mišića i omamljenosti ili pospanosti, usporavanje disanja, aspiracija, visok krvni tlak ili nizak krvni tlak, poremećaj srčanog ritma.
English: During treatment with olanzapine in combination with lithium or divalproex, an increase of ≥ 7% from baseline body weight occurred in 17.4% of patients during acute treatment (up to 6 weeks).
Croatian: Tijekom liječenja olanzapinom u kombinaciji s litijem ili divalproeksom, porast tjelesne težine ≥ 7% od početne pojavio se u 17,4%
English: If you take more ZYPREXA VELOTAB than you should Patients who have taken more ZYPREXA VELOTAB than they should have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech,
Croatian: Ako uzmete više ZYPREXA VELOTAB tableta nego što ste trebali Bolesnici koji su uzeli više lijeka ZYPREXA VELOTAB nego što su trebali imaju sljedeće simptome:
English: Other ingredients: gelatin, mannitol (E421), aspartame (E951), sodium methyl parahydroxybenzoate (E219), sodium propyl parahydroxybenzoate (E217).
Croatian: Drugi sastojci: želatina, manitol (E421), aspartam (E951), natrijev metilparahidroksibenzoat (E219), natrijev propilparahidroksibenzoat (E217).
English: ZYPREXA VELOTAB contains aspartame, mannitol and sodium methyl parahydroxybenzoate and sodium propyl parahydroxybenzoate
Croatian: ZYPREXA VELOTAB sadrži aspartam manitol, natrijev metilparahidroksibenzoat i natrijev propilparahidroksibenzoat
English: Sodium methyl parahydroxybenzoate and sodium propyl parahydroxybenzoate Olanzapine orodispersible tablet contains sodium methyl parahydroxybenzoate and sodium propyl parahydroxybenzoate.
Croatian: Natrijev metilparahidroksibenzoat i natrijev propilparahidroksibenzoat Olanzapin raspadljive tablete za usta sadrže natrijev metilparahidroksibenzoat i natrijev propilparahidroksibenzoat.
English: 5 Observed for fasting normal levels at baseline (< 1.69 mmol/l) which increased to high
Croatian: 5 Uočeno za početne normalne razine natašte (< 1,69 mmol/l) koje su porasle na visoke razine
English: • The other ingredients are - gelatin, mannitol (E421), aspartame (E951), sodium methyl parahydroxybenzoate (E219) and sodium propyl parahydroxybenzoate (E217).
Croatian: • Drugi sastojci su - želatina, manitol (E421), aspartam (E951), natrijev metilparahidroksibenzoat (E219) i natrijev propilparahidroksibenzoat (E217)
English: ZYPREXA VELOTAB orodispersible tablet contains aspartame, which is a source of phenylalanine.
Croatian: ZYPREXA VELOTAB raspadljive tablete za usta sadrže aspartam, izvor fenilalanina.
English: The exact amount is shown on your ZYPREXA VELOTAB pack.
Croatian: Točna količina navedena je na pakiranju ZYPREXA VELOTAB tableta.
English: Your doctor should do blood tests to check blood sugar and certain fat levels before you start taking ZYPREXA VELOTAB and regularly during treatment.
Croatian: Prije početka uzimanja lijeka ZYPREXA VELOTAB te redovito tijekom liječenja, liječnik bi Vam trebao obaviti krvne pretrage kako bi provjerio razinu šećera i određenih masnoća u krvi.
English: Development or exacerbation of diabetes occasionally associated with ketoacidosis or coma, including some fatal cases (see section
Croatian: glikozurija pojačan apetit razvoj ili egzacerbacija dijabetesa, ponekad povezana s ketoacidozom ili komom, uključujući i neke slučajeve sa smrtnim ishodom (vidjeti dio 4.4)11
English: Glutamyltransferase
Croatian: visoka gama glutamiltransferaza1
English: Each ZYPREXA VELOTAB orodispersible tablet contains either 5 mg, 10 mg, 15 mg or 20 mg of the active substance.
Croatian: Jedna ZYPREXA VELOTAB raspadljiva tableta za usta sadrži 5 mg, 10 mg, 15 mg ili 20 mg olanzapina.
English: In one clinical trial in patients with bipolar mania, valproate combination therapy with olanzapine resulted in an incidence of neutropenia of 4.1%; a potential contributing factor could be high plasma valproate levels.
Croatian: U jednom kliničkom ispitivanju u bolesnika s bipolarnom manijom, kombinacijska terapija valproatom i olanzapinom uzrokovala je incidenciju neutropenije od 4,1%.
English: EU/1/99/125/001 EU/1/99/125/002 EU/1/99/125/003 EU/1/99/125/004 EU/1/99/125/005
Croatian: EU/1/99/125/018 EU/1/99/125/019 EU/1/99/125/020
English: 13 Following short term treatment (median duration 22 days), weight gain ≥ 7% of baseline body weight (kg) was very common (40.6 %), ≥ 15% of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %).
Croatian: 13 Nakon kratkotrajnog liječenja (medijan trajanja 22 dana), povećanje tjelesne težine ≥ 7% od početne tjelesne težine (kg) bilo je vrlo često (40,6%), porast ≥ 15% od početne tjelesne težine bio je čest
English: • High blood sugar and high levels of fat (triglycerides and cholesterol) have been seen in patients taking ZYPREXA VELOTAB.
Croatian: • U bolesnika koji uzimaju ZYPREXA VELOTAB uočena je visoka razina šećera i masnoća u krvi (trigliceridi i kolesterol).
English: Gently push the tablet out.
Croatian: Nježno istisnite tabletu.
English: Only take other medicines while you are on ZYPREXA VELOTAB if your doctor tells you that you can. You might feel drowsy if ZYPREXA VELOTAB is taken in combination with antidepressants or medicines taken for anxiety or to help you sleep (tranquillisers).
Croatian: Ako uzimate ZYPREXA VELOTAB u kombinaciji s antidepresivima, lijekovima za tjeskobu ili lijekovima koji Vam pomažu zaspati (trankvilizeri), možete se osjećati omamljeno.
English: Excipients with known effect: Each orodispersible tablet contains 0.80 mg aspartame,
Croatian: Pomoćne tvari s poznatim učinkom: jedna raspadljiva tableta za usta sadrži 0,80 mg aspartama,
English: < 2.26 mmol/l) to high (≥ 2.26 mmol/l) were very common.
Croatian: (≥ 1,69 -< 2,26 mmol/l) do visokih vrijednosti (≥ 2,26 mmol/l) bile su vrlo česte.
English: How to take ZYPREXA VELOTAB
Croatian: Kako uzimati ZYPREXA VELOTAB
English: Excipients with known effect: Each orodispersible tablet contains 0.60 mg aspartame,
Croatian: Pomoćne tvari s poznatim učinkom: jedna raspadljiva tableta za usta sadrži 0,60 mg aspartama,
English: 0.1125 mg sodium methyl parahydroxybenzoate, 0.0375 mg sodium propyl parahydroxybenzoate.
Croatian: 0,1125 mg natrijevog metilparahidroksibenzoata, 0,0375 mg natrijevog propilparahidroksibenzoata.
English: 0.225 mg sodium methyl parahydroxybenzoate, 0.075 mg sodium propyl parahydroxybenzoate.
Croatian: 0,225 mg natrijevog metilparahidroksibenzoata, 0,075 mg natrijevog propilparahidroksibenzoata.
English: Very common symptoms in overdose (> 10 % incidence) include tachycardia, agitation/aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma.
Croatian: Vrlo česti simptomi predoziranja (incidencija > 10%) obuhvaćaju tahikardiju, agitaciju/agresivnost,
English: There is a risk of feeling drowsy when you are given ZYPREXA VELOTAB.
Croatian: Kad uzimate ZYPREXA VELOTAB postoji rizik da se osjećate omamljeno.
English: ZYPREXA VELOTAB contains the active substance olanzapine.
Croatian: Što je ZYPREXA VELOTAB i za što se koristi ZYPREXA VELOTAB sadrži djelatnu tvar olanzapin.
English: Orodispersible tablet
Croatian: Nježno istisnite tabletu
English: How to store ZYPREXA VELOTAB
Croatian: Kako čuvati ZYPREXA VELOTAB
English: INFORMATION IN BRAILLE ZYPREXA VELOTAB 20 mg
Croatian: 16. PODACI NA BRAILLEOVOM PISMU ZYPREXA VELOTAB 20 mg
English: Common side effects (may affect up to 1 in 10 people) include changes in the levels of some blood cells, circulating fats and early in treatment, temporary increases in liver enzymes ; increases in the level of sugars in the blood and urine; increases in levels of uric acid and creatine phosphokinase in the blood; feeling more hungry; dizziness; restlessness; tremor; unusual movements (dyskinesias); constipation; dry mouth; rash; loss of strength; extreme tiredness; water retention leading to swelling of the hands, ankles or feet; fever, joint pain and sexual dysfunctions such as decreased libido in males and females or erectile dysfunction in males.
Croatian: Česte nuspojave (mogu se pojaviti u najviše 1 na 10 osoba) uključuju promjene razina nekih krvnih stanica, cirkulirajućih masti u krvi te, u ranim fazama liječenja, privremena povećanja razine jetrenih enzima; povišene razine šećera u krvi i mokraći; povećanje razine mokraćne kiseline i kreatin fosfokinaze u krvi; pojačan apetit; omaglicu; nemir; nevoljno drhtanje; neuobičajene pokrete
English: A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE Name and address of the manufacturer responsible for batch release Lilly S.A., Avda.
Croatian: PROIZVOĐAČ ODGOVORAN ZA PUŠTANJE SERIJE LIJEKA U PROMET Naziv i adresa proizvođača odgovornog za puštanje serije lijeka u promet Lilly S.A., Avda. de la Industria 30, 28108 Alcobendas, Madrid, Španjolska
English: - If you get any side effects, talk to your doctor or pharmacist.
Croatian: Ako imate bilo koji od navedenih simptoma, odmah se obratite svom liječniku ili bolnici.
English: INFORMATION IN BRAILLE ZYPREXA VELOTAB 5 mg
Croatian: 16. PODACI NA BRAILLEOVOM PISMU ZYPREXA VELOTAB 5 mg